

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000103 A2

- (51) International Patent Classification⁷: **A61B**
- (21) International Application Number:
PCT/US2003/019825
- (22) International Filing Date: 24 June 2003 (24.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/391,027 24 June 2002 (24.06.2002) US
60/427,662 19 November 2002 (19.11.2002) US
60/444,143 31 January 2003 (31.01.2003) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- (71) Applicant and
(72) Inventor: **NOYES, William, R.** [US/US]; 3501 Norkota Court, Grand Forks, ND 58210 (US).
- (74) Agents: **HERBERT, Curtis, B.** et al.; Patterson, Thuente, Skaar & Christensen, P.A., 4800 IDS Center, 80 South Eighth Street, Minneapolis, MN 55402-2100 (US).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FILLERS AND METHODS FOR DISPLACING TISSUES TO IMPROVE RADIOLOGICAL OUTCOMES



(57) Abstract: Certain embodiments include a method of improvising radiological outcomes by introducing a filler to between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, and administering a dose of radioactivity to at least the first tissue location or the second tissue location. Collagen and hyaluronic acid are examples of fillers. Certain embodiments include a medical device having a biocompatible, biodegradable filler material, wherein the device comprises at least a portion that has a shape that substantially conforms to Denovillier's space between the rectum and the prostate. Certain embodiments include a kit, the kit comprising a filler and instructions for placing the filler between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location.

WO 2004/000103 A2

FILLERS AND METHODS FOR DISPLACING TISSUES TO IMPROVE RADIOLOGICAL OUTCOMES

RELATED APPLICATIONS

5 This application claims priority to U.S. provisional patents 60/427,662 filed November 19, 2002, 60/391,027 filed June 24, 2002, and 60/444,143, filed January 31, 2003, which are hereby incorporated herein by reference.

BACKGROUND

10 Over 198,100 men will be diagnosed with prostate cancer each year. Typically, forty percent will choose interstitial implant therapy, one-third of the men will choose surgery, and one third will choose external beam radiotherapy.

 Typical treatments for prostate cancer include surgical removal of the prostate (prostatectomy), freezing the prostate (cryosurgery), hormonal therapy, prostate seed implant
15 therapy, or prostate conformal radiation.

 The treatment providing the best outcome is still debatable. However, the side effects of treating prostate cancer have become less toxic and less profound with implant therapy and 3D conformal radiotherapy. Advancements in treatment positioning and target localization have significantly improved outcomes and diminished the side effects.

20 Since the conception of 3D conformal radiotherapy, physicians have paid attention to the delivered dose to the target and surrounding tissues. Investigators have been able to correlate side effects to the amount of tissue receiving a certain radiation dose. This term has been coined: dose volume histogram. For conformal radiotherapy it is conventionally preferred that the rectum receive less than 40% of the prescribed treatment dose in hopes of minimizing
25 the radiation induced side effects.

-2-

Time, distance, and shielding affect the dose that is delivered. The less time an area is exposed to radiation, the less dose delivered. The greater the distance from the radiation, the less dose delivered. Finally, more shielding will also decrease the delivered dose.

5 SUMMARY OF CERTAIN EMBODIMENTS OF THE INVENTION

It would be desirable to provide a protocol to decrease the radiation dose to the rectum during radiotherapy for prostate cancer. It is also desirable to decrease radiation treatment-induced side effects on sensitive organs resulting from other therapies and applications directed to a target organ. Certain embodiments of the present invention address these issues.

10 Certain embodiments are a medical device, the device having a biocompatible, biodegradable filler material, wherein the device comprises at least a portion that has a shape that substantially conforms to the space between two tissue locations, e.g., Denovillier's space.

Certain embodiments are a method comprising introducing a filler to between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location. Further, there maybe a step of administering a dose of radioactivity to at least the first tissue location or the second tissue location.

Certain embodiments are directed to kits having a filler, instructions for placing the filler between tissues in conjunction with a treatment, e.g., radiation or cryogenics, and an optional delivery device.

20 Certain embodiments may have a filler material that comprises an extracellular matrix molecule. Certain embodiments may have a filler material that is biodegradable in vivo in less than approximately 90 days. Certain embodiments may have at least one therapeutic agent. Certain embodiments may have a buffering agent. Certain embodiments may have a total volume or a volume of filler in the range of about 10 to about 50 cubic centimeters, wither before
25 or after the device or filler is introduced into the patient. An expandable device may be used for filler, e.g., a balloon or sponge. Or the filler material may comprise a synthetic polymer.

-3-

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 depicts the male prostate, rectum and Denovillier's space between the prostate and rectum.

Figure 2 depicts the insertion of a needle into the space between the prostate and rectum for injecting collagen therein.

Figure 3 depicts the injected collagen within Denovillier's space between the prostate and the rectum.

Figure 4 depicts a computer tomography (CT) image of a patient's pelvis showing a collagen filler placed between the prostate and rectum of the patient.

10

DETAILED DESCRIPTION

Certain embodiments of the invention comprise placing a filler between the radiation target tissue and other tissues. The filler increases the distance between the target tissue and other tissues so that the other tissues receive less radiation. In some embodiments, the filler is a degradable material that is installed once prior to the course of radiation treatment and does not require subsequent manipulation, repositioning, or removal. Some fillers maintain their natural properties during and after exposure to radiation and remain in the same location until after a treatment course has concluded. Other embodiments include fillers made with inflatable devices that are introduced between the target tissue and other tissue; such inflatable devices may be left in the patient during the course of radiation treatment or removed and reintroduced periodically during the course of radiation treatment. Certain of the embodiments set forth herein address various advantages that are described in the context of the evolution of the prostate treatment procedures.

The modern era has witnessed the evolution of radical prostatectomy, external beam radiotherapy and interstitial permanent seed Brachytherapy to a point where the results are nearly equivalent. Although some authors may debate that their technique has achieved superior

-4-

results, by and large the results have been too close to claim that one modality is definitely superior to the other. If this is so, then the decision for therapy must consider treatment related side effects.

External beam radiotherapy may cause radiation-induced side effects for prostate cancer. Modern radiation treatment using 3D conformal therapy and most recently, intensity modulated radiotherapy (IMRT) has significantly reduced treatment related side effects. However, such treatments continue to require special consideration for the rectum, which is particularly sensitive to radiation. Care is taken to ensure that the rectum receives a dose that is well tolerated and diminishes the probability of treatment related side effects. Others have evaluated the effectiveness of daily insertion of rectal catheters and daily administration of rectal radioprotectants, and have achieved only modest success.

Some investigators are attempting to decrease the dose to the anterior rectal wall and thereby decrease the potential for radiation induced side effects on the rectum. One such technique is to insert an inflatable Foley catheter into the rectum on a daily basis during radiation treatments. The premise is that more of the rectum is displaced away from the prostate than the small portion of rectum that is pushed toward the prostate. Therefore a smaller amount of rectum is receiving radiation and consequently the side effects from radiation should be diminished.

However, certain embodiments set forth herein have advantages that may include the reduction of radiation side effects, improved cost effectiveness, the need to perform only one or a few procedures to achieve a reduction in radiation, no requirement for removal of the treatment after its administration, and ease of use, e.g., by a patient, nurse, or technician.

Example 2 includes a study that shows that injection of human collagen into Denovillier's space can change the radiation dose that the rectum receives when the prostate is exposed to radiation. "Denovillier's space" is a region located between the rectum and prostate. The collagen was well tolerated and withstood the radiation treatments. The collagen degraded

-5-

in less than about sixty days and required no procedures after its initial introduction into the patients. The study was a trial involving 10 men who received human collagen injections into Denovillier's space to displace the rectum away from the prostate prior to proceeding with their radiotherapy. The injections were well tolerated and could readily be performed on an outpatient
5 basis. The radiation dose to the rectum was diminished by over approximately 50% when 20 cc's of human collagen was injected into Denovillier's space. Moreover, men who have received human collagen injections appeared to have minimal rectal side effects associated from their radiotherapy and had no appreciable changes associated due to the collagen.

This procedure was well-tolerated by the patients. Indeed, others have reported
10 that human collagen has been used in various body areas and is well tolerated. For example, it has been injected into a the perineum in hopes of improving urinary incontinence. And human collagen has received United States Food and Drug Administration approval to be used in brachytherapy procedures as a spacer. Further, it is known that normal saline may be injected into the potential space between the rectum and prostate prior to proceeding with cryotherapy to
15 minimize the freezing effect on the rectum, so displacement of the tissues around Denovillier's space is known to be well-tolerated.

The successful use of collagen as a filler shows that other materials may also be used. Other materials may include natural or synthetic materials, e.g., proteins, extracellular matrix molecules, fibrin, proteins, hyaluronic acid, albumin, bulking agents, and polyethylene
20 glycol-based materials. A synthetic material is a material that is not found in nature.

Certain embodiments provide a method of displacing a tissue to protect the tissue against the effects of a treatment involving radiation or cryotherapy. One embodiment involves using a filler to displace the tissue relative to a tissue that is to receive the treatment. Another embodiment involves introducing a filler to displace a first tissue and radiating a second tissue,
25 particularly a second tissue that is close to the first tissue. In another embodiment, the method comprises the steps of injecting a filler into a space between tissues; and may further include

irradiating one of the tissues so that the other tissue receives less radiation than it would have in the absence of the filler.

Certain embodiments also provide methods for treating a tissue of a body by radiation. In one embodiment, the method comprises the steps of injecting an effective amount
5 of a filler into a space between a first tissue (e.g., prostate) of a body and a second tissue (e.g., rectum), which can be a critically sensitive organ; and treating the first tissue by radiation whereby the filler within the space reduces passage of radiation into the second tissue. Tissue is a broad term that encompasses a portion of a body: for example, a group of cells, a group of cells and interstitial matter, an organ, a portion of an organ, or an anatomical portion of a body, e.g., a
10 rectum, ovary, prostate, nerve, cartilage, bone, brain, or portion thereof.

Also provided are embodiments for displacing a sensitive body tissue relative to another body tissue that is the target of a treatment protocol, to effectively reduce side effects on/in the sensitive tissue induced by or resulting from a treatment directed to the target tissue. In one embodiment, the method comprises injecting a filler into a space between the sensitive body
15 tissue (e.g., rectum) and the target body tissue (e.g., prostate); and conducting a treatment protocol on the target body tissue whereby the sensitive body tissue is less affected by the treatment as a result of the presence of the filler.

Examples of embodiments of the treatment include use with such applications as external beam radiotherapy (e.g., 3D conformal or Intensity Modulated Radiotherapy),
20 interstitial prostate brachytherapy (e.g., using permanent or temporary seeds, or using High Dose Rate remote after loading), and cryosurgery. Another embodiment is the use of these techniques for brachytherapy radiation treatments for prostate cancer or gynecological cancers. Brachytherapy includes the placement of a radioactive isotope within or near the tumor, target organ, or other tissue. For example, a brachytherapy technique is placement of permanent I-125
25 radioactive seeds into the prostate for treatment of prostate cancer. Applications for gynecology

-7-

include embodiments involving displacing a tissue from another tissue that is to be targeted by radiation.

A filler is a substance that occupies a volume after its introduction into a body. Examples of fillers include but are not limited to polymers, gels, sols, hydrogels, sponges, bulking agents, and balloons. Filler materials include polysaccharides, alginate, collagen, gelatin, fibrin, fibrinogen, albumin, serum, autologous serum, sutures, and natural and synthetic polymers. Synthetic polymers include polylactide, polyglycolide, polycaprolactones, poly(alpha.-hydroxy acid), poly(amino acid), and poly(anhydride). Fillers may be crosslinked or uncrosslinked. Polymers include polyethylene glycol and derivatives thereof, including crosslinked polyethylene glycols. Other types of polymers include thermoreversible and thixotropic polymers. Other examples of a filler include self-absorbing suture material held within a suspension (such as prolene sutures).

Fillers may include materials that are formed in situ in the body, e.g., by combining a first precursor and a second precursor to form a material, e.g., a gel or hydrogel. Examples include covalent bonding of electrophiles and nucleophiles (e.g., see U.S. Patent No. 5,874,500) and gelation of polysaccharides (e.g., addition of calcium to alginate). Fillers may include materials derived from the body that receives them, e.g., autologous serum. Donor blood may be used to derive some materials, e.g., albumin. Combinations of materials are also contemplated.

Suitable fillers and materials for fillers may include, for example, those set forth in U.S. Patents Nos. 6,509,031; 6,413,742; 6,388,047; 6,280,772; 6,271,278; 6,268,405; 6,129,761; 6,031,148; 6,110,484; 5,932,539; 5,874,500; 5,863,984; 5,865,367; 5,759,583; 5,618,563; 5,599,552; 4,970,298; 4,703,108; and 4,193,813, which are hereby incorporated by reference in their entirety herein.

Fillers may be biodegradable, either by hydrolysis, proteolysis, the action of cells in the body, or a combination thereof. Biodegradation may be measured by palpitation or other

observations to detect the change in volume of a filler after its introduction into a patient. Biocompatible materials are preferred, especially collagen or hyaluronic acid. A suitable length for biodegradation to occur is between one day weeks and twelve months after introduction of the filler into the body. Alternatively, fillers may remain in place for other periods, including
5 from one week to three months and two to eight weeks. Also the filler may be biodegraded in less than about two months after implantation, as is preferable for the case of displacing rectal tissue from the prostate gland. The time for biodegradability for a specific use may be determined by the time required to complete a course of radiation, which may vary for different radiological applications and different requirements for administering the full course of
10 radiological therapy.

Fillers may include osmotic agents. For example, agents that increase the osmotic pressure of the filler may be used in the filler. One advantage of an osmotic agent is that it will cause the filler to increase its volume after its introduction into the body. For example, albumin, human serum, human plasma, salts, or steroids may be added to, or mixed with, the filler.

15 Fillers may contain drugs or be used to deliver drugs. For example, a steroid may be introduced into the filler. Drugs may include, for example, steroids, anti-inflammatory agents, agents to inhibit degradation of the filler (e.g., protease inhibitors), agents to enhance filler degradation, antibiotics, hemostatics, and antimycotics.

20 Fillers may also be reversibly introduced. For example, a thermoreversible polymer may be introduced as a liquid-like material and allowed to form a gel in situ. Or a polymer may be introduced that is non degradable or poorly degradable until it is heated to cause its degradation or liquefaction.

A filler may have a first physical state before its introduction into the body and a second physical state after its introduction into the body. A change in physical state may
25 include, for example, a change in volume, viscosity, water content, swelling, or crosslinking.

Another embodiment is a filler that exists as at least two precursors before introduction into the body and exists as a crosslinked material formed by the mixing of the two precursors after introduction into the body.

For example, solutions containing collagen or collagen-like precursors may be introduced into the body. As the solution warms to the body temperature as the pH of the solution becomes adjusted to bodily pH, the fibrils cooperate to form a fibrin gel according to well-known processes of collagen formation. The solution has a low viscosity while stored, e.g., as part of a kit, but has a stronger physical structure after its self-assembly in situ in the patient.

And for example, solutions of polysaccharides may be introduced into the patient. Some polysaccharides increase in viscosity when exposed to certain salts, or in response to a change in pH. Products and processes involving, for instance, hyaluronic acid solutions or precursors that gel after introduction into a patient are known.

A solution that contains a filler gels in response to a change in pH may be made up at a first pH in solution, but be buffered so that its pH changes after introduction into a patient. The buffer could be relatively weak compared to physiological buffer saline solutions, or it could be concentrated. In either case, the buffer would eventually diffuse away so that the pH of the filler would be changed.

Similarly, a solution having a filler that changes viscosity, crosslinks, or gels in response to a change in temperature could be introduced at a first temperature and allowed to transition to body temperature in situ in a patient so that it would have a change in properties.

Fillers may be mixed with salts, buffers, or other pharmaceutically acceptable agents, e.g., carriers. Examples of suitable pharmaceutical carriers are described, for example, in "Remington's Pharmaceutical Sciences" by E. W. Martin. Examples of buffers include phosphates, carbonates, and Tris. Examples of buffer osmolarity are ranges from 10 to 3000, from 50 to 600, from 150 to 500, and from 300-350. A buffering agent may be both a buffer and

-10-

an osmolarity agent. Fillers may also be mixed with agents to aid their visualization by medical devices, e.g., by MRI or ultrasound. Fillers may also be mixed with agents that block radiation.

If the filler contains collagen, the collagen may be natural or synthetic collagen, and of human origin or non-human origin, such as bovine collagen (e.g., Bovine Type I collagen), for example. The collagen can be prepared as a suspension with a pharmaceutically acceptable vehicle or carrier (e.g., water) having a pH in the physiological range. Collagen may be collagen derived from a natural source, and may include collagen isolated from tissue and recombinantly derived collagen, e.g., collagen produced by genetically engineered bacteria. Collagen may also be collagen that is not found in nature, e.g., materials intelligently designed to mimic collagen or some of the structural or functional features of collagen.

Other examples of fillers are hyaluronic acid, cellulose, alginate, and gelatin, which are available from commercial sources, e.g., Sigma-Aldrich, Inc. and ICN Biomedicals, Inc. Hyaluronic acid is a material that is accepted in the medical community as a material that may be implanted into a patient; other commercial sources are Genzyme Advanced Biomaterials (e.g., HyluMed®), LifeCore Biomedical, and FMC BioPolymer. Another example of a filler is cellulose, e.g., Avicel® a thixotropic cellulose product from FMC BioPolymer. Another filler example is synthetic polymer hydrogels, e.g., as made by Angiotech Pharmaceuticals, e.g., Coseal®. Other fillers are described in, e.g., U.S. Patent No. 6,224,893, and other references set forth herein.

Another embodiment is a filler that comprises a device having a reversible volume, for example, a balloon. A balloon may be introduced, inflated, and then deflated after a dose of radiation has been administered, or recovered after the radiation treatment has been completed.

In use, a device for delivering a filler to a body may be loaded with a filler, and the filler introduced into the body, preferably so that the distance between a first and a second tissue in the body is thereby increased. A further step may include administering a dose of

radiation to a tissue, preferably so that the second tissue receives less radiation than it would have received if the distance between the first and second tissue had not been increased. A further step may also be administration of cryogenic treatment to the first or second tissue or a tissue nearby. The radiation may alternatively be directed to a third tissue so that the first tissue or the second tissue received a lower amount of radiation as a result of its separation from the other tissue(s). The first tissue and the second tissue may be adjacent to each other in the body, or may be separate from each other by other tissues. In many cases, such separation does not reduce the beneficial effects of achieving separation between the first and second tissue.

Filler volumes for separating tissues are dependent on the configuration of the tissues to be treated and the tissues to be separated from each other. In many cases, a volume of about 20 cubic centimeters (cc's or mls) is suitable. In other embodiments, as little as 1 cc might be needed. Other volumes are in the range of 5-1000 cc, and all ranges therebetween, e.g., 5-400 cc, 10-30 cc, 15-25, cc, 10-150 cc, 20-200 cc, 15-500 cc, 50-1000 cc, and 30-200 cc. In some embodiments, fillers are administered in two doses at different times so as to allow the tissues to stretch and accommodate the filler and thereby receive a larger volumes of filler than would otherwise be readily possible.

An example of a delivery device is a syringe. The filler is loaded into the syringe and injected through a needle into a body. Another example is a device that accepts, e.g., a folded, deswelled, or rolled filler and provides a propelling mechanism to propel the filler through a needle or catheter into a body. Propulsion may be by, e.g., a handle, a plunger, gas, or liquid force.

Another embodiment is a kit for introducing a filler into a body. The kit may include a filler and a device for delivering the filler to the body. The filler may be capable of undergoing a change in state after its introduction into the body: for example, a collagen solution forms a collagen gel after entering the body, and a dehydrated sponge imbibes water to increase its volume after exposure to physiological conditions. Embodiments include instructions for use.

-12-

Embodiments include anesthetics mixed with the filler or separate therefrom. Embodiments include kits wherein the delivery device is a syringe, and other embodiments include a needle for the syringe, and may include a needle for administering the filler and/or the anesthetic.

Instructions may be included with a kit. Instructions may include words that
5 direct a user in a use of a kit. Instructions may be fully or partially included with the kit, including as an insert, on a label, on a package, in a brochure, a seminar handout, a seminar display, an internet teaching course, or on an internet or intranet web site. For example, a label on a kit could reference an internet address having instructions. Instructions may include explanations of embodiments set forth herein. Instructions may include dose histograms, and
10 explanations of suitable filler volumes for use.

Preferred anesthetics are local anesthetics, particularly 1% lidocaine for use in applying a filler to a body to displace the rectum from the prostate gland. The lidocaine may be used to perform a nerve block. A preferred needle for anesthetic application is a short 22-gauge needle and a 7 cm 22-gauge spinal needle. A preferred needle for delivering a filler via syringe
15 injection is an 8-gauge spinal needle that is 3.5 cm length. Kit may include anesthetics.

EXAMPLE 1: Sample protocol

This example describes a protocol for reducing the radiation exposure of a tissue by increasing the distance between the tissue and a nearby tissue that is to be target for
20 radioactive treatment. This example is cast in terms of using a space between the rectum and prostate, but any two tissues, or portions thereof, may be separated by following this protocol and introducing the filler between the tissues instead of into Denovillier's space. Human collagen is used as the filler, but other fillers may be substituted.

Protocol:

- 25 a) Inject human collagen into the space (Denovillier's space) between the rectum and prostate.

-13-

- 5 b) Administer an effective volume of human collagen into Denovillier's space to decrease the radiation dose to the rectum during radiation therapy of the prostate, and change the rectal dose volume histogram.
- c) Assess the effectiveness of human collagen in lowering the dose of radiation to the rectum during prostate radiation therapy.
- d) Evaluate the acute side effects of radiation during therapy compared to historical controls.

Patient eligibility:

- 10 a) Male with biopsy-proven prostate cancer.
- b) Age: > 18 years of age.
- c) Elected conformal radiotherapy for cure or for palliation, i.e., local control due to known metastases.
- d) Suitable to undergo a transrectal ultrasound for determination of
15 space between rectum and prostate.
- e) Suitable to receive a local anesthetic prior to receiving the human collagen injection.
- f) Tolerated a subcutaneous injection of human collagen to rule out hypersensitivity to the collagen products.
- 20 g) Signed a study specific consent form.

Patient Contraindications:

- a) Allergic to human collagen injection.
- b) Does not tolerate human collagen injection for any reason.

Protocol Treatment - Methods and Materials

- 25 A. Prior to proceeding with the collagen injection, a diagnostic CT scan of the pelvis or a planning CT scan of the pelvis will be performed with the patient in the supine

-14-

treatment position. Prior to obtaining the planning CT scan, a Foley catheter will be inserted into the bladder and drained. Fifty cc's of 50% diluted Conray will be instilled into the bladder for visualization. The Foley catheter will then be removed. Five cc's of 50% diluted Conray will be injected into the penile urethra and retained with a penile clamp for delineation. A rectal tube will be inserted into the rectal vault. Thirty-five cc's of diluted contrast will be injected into the rectal vault for delineation. The planning CT scan of the pelvis will be obtained.

The outside surface of the prostate, bladder and rectum will be contoured (e.g., computer outlining of organs). The rectal contour will extend from the anal verge up to the rectosigmoid junction or to the top of seminal vesicles, whichever is greater, provided there is adequate pelvic parenchymal space so that minimal radiation dose is delivered to the upper rectum.

A complex 3-D isodose treatment plan with a 3-D rectal dose volume histogram (DVH) will be generated using a conformal six-field technique. Pre-injection and post-injection measurements will be determined between the anterior rectal wall and the posterior border of the prostate.

B. Procedure to place the filler.

The patient will be placed in the dorsolithotomy position with both legs up in stirrups. The transrectal ultrasound probe will be placed within the rectal vault. A syringe with a 20-gauge needle will be used to administer a local anesthetic. Preferably, a nerve block is performed to the inferior branch of the pudendal nerve using a 7cm 22-gauge spinal needle to administer 5cc of 1% lidocaine to the left and right para-vesicular region located just laterally of the seminal vesicles. A second syringe with a 16-gauge spinal needle will be inserted into the perineum and rotated to increase the potential space between the rectum and prostate. The same syringe will inject normal saline into the

-15-

space between the rectum and prostate to further increase the capacity of this potential space.

Once the normal saline has been injected, a third syringe with a 16-gauge spinal needle will be used to inject a 5-10 mm layer of human collagen along the posterior wall of the prostate between the prostate and rectum. Once the collagen has been injected into the space between the rectum and prostate, ultrasound images will be obtained to determine the echogenicity of the collagen as well as to correlate the measured ultrasound volume to the CT obtained volume. All used syringes will be discarded in a safe manner.

10 C. A second planning CT scan of the pelvis with simulation will be performed after placement of the collagen injection using the same technique. A 3-D computer generated isodose treatment plan will be generated with a rectal DVH. Differences between the rectal DVH's will be noted.

15 D. The patient will then proceed with the conformal radiotherapy to a dose of about 7560 cGy in 42 daily treatment fractions.

E. During the course of treatment, the patient will be monitored for changes in bowel frequency, symptoms of proctitis, and amount of medications used if necessary.

20

F. A third planning CT with simulation will be performed on the first five patients after they have received 15-20 daily radiation treatments. If there has been no significant reduction in collagen volume nor significant changes in the rectal dose per the DVH, the third planning CT scan will be discontinued.

25

-16-

G. A fourth planning CT scan with simulation will be performed on the last day of treatment. Again, a 3-D complex computer plan will be generated to determine the rectal DVH. Measurements will be compared to the previous DVH's. If there has been no significant reduction or change in collagen volume nor significant changes in the rectal dose per the DVH, the fourth planning CT will be discontinued after 20 patients.

H. A fifth planning CT scan with simulation and simulation for dosimetric purposes will be performed approximately 4-6 months after completion of the radiation therapy or 6-8 months after the injection of collagen into the space between the rectum and prostate.

This scan will be performed for the first five patients and than discontinued.

Treatment Evaluation:

The results will provide the following information:

- Toleration of injection of human collagen into the space between the rectum and prostate.
- Extent of anterior displacement of prostate from injection of human collagen.
- Amount of radiation dose delivered to anterior wall of rectum.
- Amount of dose reduction to rectum per dose volume histogram (DVH).
- Clinical changes of bowel habits and treatment intervention during the course of radiation treatments, if any.

Descriptive Factors:

- Relationship of cc's of human collagen to forward displacement of prostate.

- Description of homogeneous distribution of human collagen between rectum and prostate as determined per ultrasound and CT scan.
- Relationship of cc's of human collagen to change of rectal dose volume histogram.

5

Nursing Evaluation and Treatment Follow-up:

A weekly assessment of patients will include a review of tolerance of treatment, bowel habit changes and treatment interventions. Typically, medical interventions can include but are not limited to anti-hemorrhoidal creams/ointments, anti-diarrhea medications, anti-spasmodic medications, alpha-1 inhibitors and analgesics with or without narcotics.

10

Patient review will be conducted at 2 weeks, 1 month, 3 months and 6 months after completion of radiation therapy. The patient will than be followed on a routine serial basis that is recommended for all cancer patients after receiving radiation therapy.

	Number of BM's per day	Consistency Normal = N Soft = S Hard = H Loose = 1	Anal Discomfort	Anti-diarrhea Medication	Anti-Hemorrhoid Medication	Incontinence of Urine (U) or Stool (S)
Consultation						
Day 1 of XRT						
Wk 1						
Wk 2						
Wk 3						
Wk 4						
Wk 5						
Wk 6						
Wk 7						
Wk 8						
2 Weeks						
1 Month						

3 Months						
6 Months						
1 Year						
1.5 Years						
2 Years						
2.5 Years						
3 Years						

Human Collagen:

Human collagen is commercially available from multiple manufacturers. Human collagen has been FDA approved to be injected into patients and in particular the pelvis and perineurium of humans. The FDA has also approved the use of human collagen during radiation brachytherapy. Brachytherapy will deliver a dose that is believed to be immeasurable at the surface of the radioactive isotope but can range from 300-600 Gy or greater. The traditional radiation dose delivered to the prostate ranges from 70-76 Gy. However, modern technology using 3-D conformal radiation or Intensity Modulated Radiotherapy (IMRT) has allowed dose escalation upwards to 100 Gy. These doses are well below the dose of 145 Gy used for brachytherapy or the surface dose of a radioactive isotope.

Human collagen is typically commercially supplied in preloaded syringes containing 5 or 10 cc's of collagen. The unit is sterile and comes sealed. The pack will be stored and inspected for damage prior to being opened. If one suspects a damaged product, it will not be used. The human collagen will be removed from its package only prior to undergoing the injection procedure as previously outlined.

Protocol. A syringe with an anesthetic will be used to obtain local anesthesia. A second needle will be inserted into the perineum between the potential space between the rectum and prostate. This needle will be rotated to further open the space between the rectum and prostate

-19-

(Denovillier's space), and normal saline will then be injected to further increase this potential space. The human collagen will then be injected into this space using ultrasound guidance.

Once the human collagen has been injected into the perineum as desired, the used syringes will be discarded in a safe manner.

5

EXAMPLE 2: Treatment of ten males

This protocol involved injecting an effective volume of human collagen into Denovillier's space to displace the rectum away from prostate. A conventional computer plan used for radiation treatment planning was used to determine the reduction of dose to the rectum (dose volume histogram) corresponding to the collagen injection. Accordingly, patients were monitored during their 2 months of radiation treatments to assess acute radiation induced side effects.

Ten men with stage 1 or stage 2 prostate cancer were informed of the ongoing procedure and elected to participate.

15

Prior to the collagen injection, each patient underwent a CT simulation to obtain CT images to be used for a radiation computer intensity modulated radiotherapy (IMRT) treatment plan without human collagen. All men received their human collagen injection from the same urologist as an outpatient. To perform the injection, each man was placed in the left lateral decubitus position. An ultrasound transducer was positioned into the rectum so that the entire prostate was well visualized. A 7 inch 22 gauge spinal needle was used to perform a bilateral pudendal nerve block using 2% lidocaine. After obtaining adequate anesthetic effect, a 5.5 inch 18 gauge spinal needle was positioned into the space between the rectum and prostate using ultrasound guidance. Once the needle location was believed to be within Denovillier's space, 5-10 cc's of normal saline was injected to open the potential space between the rectum and prostate. Real time ultrasound guidance was used to confirm that the needle was anterior to the rectal wall and posterior to the prostate and therefore within Denovillier's space. This

20
25

-20-

process is depicted in Figures 1-3, with patient 100 having space 102 between rectum 104 and prostate 106 receiving needle 108 into space 102, with needle 108 being in communication with syringe 110 that contains collagen filler 112. The syringe plunger is depressed to introduce collagen filler 112 into space 102.

5 Once it was confirmed that the normal saline was within Denovillier's space, the protocol proceeded to the injection of human collagen using the same 5.5 inch gauge 18 spinal needle. Each of the 10 men who entered into the protocol received 20 cc's of human collagen. Their prostate volumes ranged from 35 cc up to 90 cc's.

10 Following placement of 20 cc's of human collagen, the needle was removed and then the ultrasound transducer. Approximately, 5 days following the collagen injection each man underwent a second CT simulation to obtain a second IMRT radiation computer treatment plan with the collagen injection. Five days were provided to allow reabsorption of the normal saline and the human collagen to "settle" within Denovillier's space.

15 Figure 4 depicts a CT scan of a man that received a collagen filler. The man 200 received about 20 cc of collagen filler into the space 212 between rectum 204 and prostate 206. The space 204 is enlarged so that the radiation exposure of rectum 204 is reduced.

20 The first and second IMRT radiation computer treatment plans were compared to evaluate the displacing properties of human collagen and assess the reduction in radiation dose to the rectum. A third IMRT radiation computer treatment plan was obtained on the last day of treatment to confirm that there had been minimal change throughout their treatment.

 During the 2 months of external beam radiation, each person was interviewed on a weekly basis. Quality of life issues were assessed regarding their urinary and bowel habits.

 CT scans were obtained 6 months and 12 months following completion of their radiotherapy to monitor absorption of human collagen.

25 Results: Each man who elected to proceed with the ongoing protocol tolerated the collagen injection very well. No one reported symptoms suggestive of an allergic reaction. Three men

reported a sensation similar to a light rectal pressure that resolved 3-4 hours after the injection. One man experienced urinary retention and required placement of a Foley catheter. The catheter was removed 3 days after the injection without difficulty or recurrence. It is believed that the urinary retention was secondary to the pudendal nerve block.

5 All men received prostate treatment to a dose of 75.6 Gy in 42 fractions. Their treatment was delivered using an IMRT 6-field technique. Conventionally, a highly positive outcome is if 30% of the rectum receives 45 Gy or less and 10-15% receives 60 Gy or more.

All of the patients had 20-25% of the rectum receiving 45 Gy or less prior to the collagen injection. Following the collagen injection, 7-15% of the rectum received 45 Gy or
10 less. Moreover, <5% of the rectum received a dose of 60 Gy or more.

All men who received a collagen injection prior to their radiation treatments experienced no change in their bowel habits. Interestingly, one man underwent an unplanned flexible sigmoidoscopy 6 months after completing his radiotherapy. His physician who performed the sigmoidoscopy reported an entirely normal exam without any evidence of
15 radiation treatments.

Five of the 10 men experienced urinary frequency, diminished urinary flow and urgency. Four men elected to be treated with an alpha 1 blocker (Flomax) with success.

* * * *

20 The invention has been described in language more or less specific as to structural and methodical features and by reference to detailed examples and methodologies. It is to be understood, however, that the invention is not limited to the specific features shown and described, since the means herein disclosed comprise preferred forms of putting the invention into effect, and the examples are not meant to limit the scope of the invention. It should be
25 understood that variations and modifications may be made while remaining within the spirit and scope of the invention, and the invention is not to be construed as limited to the specific

embodiments described or as shown in the drawings. All patents, patent applications, journal references, and publications referenced herein are hereby incorporated by reference herein.

CLAIMS

1 1. A medical device, the device comprising a biocompatible, biodegradable filler material,
2 wherein the device comprises at least a portion that has a shape that substantially conforms to
3 Denovillier's space.

1 2. The medical device of claim 2 wherein the filler material comprises an extracellular
2 matrix molecule.

1 3. The medical device of claim 2 wherein the extracellular matrix molecule is collagen.

1 4. The medical device of claim 2 wherein the filler material consists essentially of collagen.

1 5. The medical device of claim 1 wherein the filler material comprises at least one
2 polysaccharide.

1 6. The medical device of claim 5 wherein the at least one polysaccharide is hyaluronic acid.

1 7. The medical device of claim 1 wherein the filler material is biodegradable in vivo in less
2 than approximately 90 days.

1 8. The medical device of claim 1 further comprising a degradation inhibitor.

1 9. The medical device of claim 1 wherein the filler material is a member of the group
2 consisting of alginate, gelatin, fibrin, fibrinogen, albumin, polylactide, polyglycolide,

-24-

3 polycaprolactone, poly(alpha-hydroxy acid), polyethylene glycol, thixotropic polymers,
4 thermoreversible polymers, and mixtures thereof.

1 10. The medical device of claim 1 further comprising a radio opaque marker.

1 11. The medical device of claim 1 further comprising at least one therapeutic agent.

1 12. The medical device of claim 11 wherein the at least one therapeutic agent is a member of
2 the group consisting of an anti-inflammatory drug, an antibiotic, an antimycotics, a hemostat, a
3 steroid, and an analgesic.

1 13. The medical device of claim 1 further comprising an osmotic agent that causes water to
2 become associated with the filler material by osmosis.

1 14. The medical device of claim 1 further comprising a buffering agent.

1 15. The medical device of claim 1 wherein the filler material comprises a synthetic polymer.

1 16. The medical device of claim 1 wherein the device has a volume in the range of 10 to 200
2 cubic centimeters.

1 17. A method comprising introducing a filler to between a first tissue location and a second
2 tissue location to increase a distance between the first tissue location and the second tissue
3 location, and administering a dose of radioactivity to at least the first tissue location or the
4 second tissue location.

1 18. The method of claim 17 wherein the first tissue location is associated with the rectum and
2 the second tissue location is associated with the prostate gland.

1 19. The method of claim 17 wherein the filler is introduced into Denovillier's space.

1 20. The method of claim 17 wherein the first tissue location is located on a tissue that is a
2 member of the group consisting of an ovary, a nerve, a cartilage, a bone, and a brain.

1 21. The method of claim 17 wherein the filler comprises a member of the group consisting of
2 alginate, gelatin, fibrin, fibrinogen, albumin, polylactide, polyglycolide, polycaprolactone,
3 poly(alpha-hydroxy acid), polyethylene glycol, thixotropic polymers, thermoreversible polymers,
4 and mixtures thereof.

1 22. The method of claim 17 wherein the filler comprises at least one therapeutic agent.

1 23. The method of claim 22 wherein the at least one therapeutic agent is a member of the
2 group consisting of an anti-inflammatory drug, an antibiotic, an antimycotics, a hemostat, a
3 steroid, and an analgesic.

1 24. The method of claim 17 wherein the filler is biodegradable in vivo in less than
2 approximately 90 days.

1 25. The method of claim 17 wherein the filler is an expandable device.

1 26. The method of claim 25 wherein the expandable device is a balloon.

- 1 27. The method of claim 26 wherein the expandable device is a sponge.
- 1 28. The method of claim 17 wherein the filler comprises a biocompatible, biodegradable
2 material.
- 1 29. The method of claim 28 wherein the biocompatible, biodegradable material comprises an
2 extracellular matrix molecule.
- 1 30. The method of claim 28 wherein the biocompatible, biodegradable material consists
2 essentially of collagen.
- 1 31. The method of claim 28 wherein the filler comprises at least one polysaccharide.
- 1 32. The method of claim 31 wherein the at least one polysaccharide is hyaluronic acid.
- 1 33. The method of claim 28 wherein the filler further comprises a member of the group
2 consisting of a degradation inhibitor, a radio opaque marker, and an osmotic agent that causes
3 water to become associated with the filler material by osmosis.
- 1 34. The method of claim 28 wherein the filler further comprises a buffering agent.
- 1 35. The method of claim 17 wherein the filler comprises a member of the group consisting of
2 a degradation inhibitor, a radio opaque marker, and an osmotic agent that causes water to
3 become associated with the filler material by osmosis.
- 1 36. The method of claim 17 wherein the filler comprises a buffering agent.

- 1 37. The method of claim 17 wherein the filler material comprises a synthetic polymer.
- 1 38. The method of claim 17 wherein the filler occupies a volume in the range of about 10 to
2 about 200 cubic centimeters in a patient.
- 1 39. A kit, the kit comprising a filler and instructions for placing the filler between a first
2 tissue location and a second tissue location to increase a distance between the first tissue location
3 and the second tissue location so that the increased distance would change an amount of
4 radiation received by at least the first tissue location or the second tissue location when at least
5 the first tissue location or the second tissue location receives a dose of radiation.
- 1 40. The kit of claim 39 wherein the instructions provide for introducing the filler into
2 Denovillier's space.
- 1 41. The kit of claim 39 herein the filler an expandable device.
- 1 42. The kit of claim 41 wherein the expandable device is a balloon.
- 1 43. The kit of claim 39 wherein the instructions describe a first tissue location located on a
2 tissue that is a member of the group consisting of an ovary, a nerve, a cartilage, a bone, and a
3 brain.
- 1 44. The kit of claim 39 wherein the instructions describe the first tissue location as being
2 associated with the rectum and the second tissue location is being associated with the prostate
3 gland.

1 45. The kit of claim 39 wherein the filler comprises a member of the group consisting of
2 alginate, gelatin, fibrin, fibrinogen, albumin, polylactide, polyglycolide, polycaprolactone,
3 poly(alpha-hydroxy acid), polyethylene glycol, thixotropic polymers, thermoreversible polymers,
4 and mixtures thereof.

1 46. The kit of claim 39 wherein the filler comprises at least one therapeutic agent.

1 47. The kit of claim 46 wherein the at least one therapeutic agent is a member of the group
2 consisting of an anti-inflammatory drug, an antibiotic, an antimycotics, a hemostat, a steroid, and
3 an analgesic.

1 48. The kit of claim 39 wherein the filler is biodegradable in vivo in less than approximately
2 90 days.

1 49. The kit of claim 39 wherein the filler comprises a biocompatible, biodegradable material.

1 50. The kit of claim 39 wherein the biocompatible, biodegradable material comprises an
2 extracellular matrix molecule.

1 51. The kit of claim 39 wherein the biocompatible, biodegradable material consists
2 essentially of collagen, hyaluronic acid, or a mixture of thereof.

1 52. The kit of claim 39 wherein the filler comprises at least one polysaccharide.

1 53. The kit of claim 39 wherein the at least one polysaccharide is hyaluronic acid.

1 54. The kit of claim 39 wherein the filler further comprises a member of the group consisting
2 of a degradation inhibitor, a radio opaque marker, and an osmotic agent that causes water to
3 become associated with the filler material by osmosis.

1 55. The method of claim 39 wherein the filler further comprises a buffering agent.

1 56. The kit of claim 39 further comprising a device for delivering the filler.

1 57. The kit of claim 39 wherein the device for delivering the filler comprises a syringe.

1 58. The kit of claim 39 wherein the instructions relate administration of the filler to radiation
2 doses received by the first tissue location, the second tissue location, or both the first tissue
3 location and the second tissue location.

1 59. The kit of claim 39 wherein the filler comprises a synthetic polymer.

1

1 60. The kit of claim 39 wherein the filler has a volume in the range of 10 to 200 cubic
2 centimeters after being introduced into a patient.

1 61. The kit of claim 39 wherein the filler has a volume in the range of 5 to 400 cubic
2 centimeters after being introduced into a patient.

Fig. 1




Fig. 2




Fig. 3




Fig. 4

